REGENERATIVE MEDICINE AND STEM CELL PRODUCTION CENTER
Liv Hospital Regenerative Medicine and Stem Cell Production Center, which allows stem cell productions to be performed in a safe hospital environment and quality for the first time in Turkey with its appropriate equipment in world standards and experienced team, provide stem cells and cellular therapy productions to clinical units from different disciplines in the framework of legal and ethical rules.
Treatment with human the cells and stem cells of the person, which is one of the most important personalized treatment options, is used in significant areas from aesthetic and cosmetic surgery to orthopedics nowadays.
Cellular products produced in Liv Hospital Regenerative Medicine and Stem Cell Production Center may be a treatment option for the following health problems;
Steroid-refractory acute graft-versus-host disease (GVHD): Mesenchymal stem cells are used in acute GVHD prophylaxis developed after allogeneic stem cell transplantation due to strong immune suppressive effects and treatment. It was shown that it is particularly effective in the skin and bowel involvement in patients with stage III-IV steroid-refractory GVHD, and 6 out of 8 patients were treated. However, MSCs were applied in more than 250 GVHD cases in our country and it has been reported that the success rates are quite high. American Society for Blood and Marrow Transplantation treatment has reported that the use of MSCs, which has the approval of use of allogeneic mesenchymal stem cells in steroid-refractory GVHD since 2010, does not carry long-term risk after application.
The cellular products that are isolated and produced in our center, which has received production permit from the Ministry of Health to implement for all of these indications to our patients, are as follows:
Cellular products outside of these products prepared at the bedside of the patient without any cell replication and applied in the same session.
Liv Hospital (LivMedCell) also contributes to clinical trials and research studies continuing in the universal aspect for many diseases, particularly including neuro- and muscular- degenerative diseases that cannot be treated today with conventional medical treatment methods, as well as performing approved cellular therapy applications. Currently, the cells of Phase 1/2 study of Duchenne Muscular Dystrophy (muscle wasting) disease involving 10 patients and approved by the Ministry of Health are produced in our center.
Stem cells that will be used in practice for many diseases within the scope of projects planned to start after taking the necessary legal permits from the relevant councils of the Ministry of Health will be produced by our center. Stem cell production for these studies will take place after the necessary legal permits.Back